Vardenafil: A Review of its Use in Erectile Dysfunction

Drugs

Volumn 63, Issue 23, 2003, Pages 2673-2702

  Keating, Gillian M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Erectile dysfunction; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Vardenafil

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTACID AGENT; CIMETIDINE; CYTOCHROME P450 INHIBITOR; DIGOXIN; DRUG METABOLITE; ERYTHROMYCIN; GLIBENCLAMIDE; GLYCERYL TRINITRATE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NIFEDIPINE; NITRATE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; RITONAVIR; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; UNINDEXED DRUG; VARDENAFIL; WARFARIN;

ANGINA PECTORIS; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLOR VISION DEFECT; DIABETES MELLITUS; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; GERIATRIC PATIENT; GRAPEFRUIT JUICE; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; IC 50; INTERNATIONAL INDEX OF ERECTILE FUNCTION QUESTIONNAIRE; NONHUMAN; PROSTATECTOMY; QUESTIONNAIRE; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; SYNCOPE;

CITRUS X PARADISI;

EID: 0344513916     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363230-00010     Document Type: Review

References (85)

1. Jardin A, Wagner G, Khoury S, et al. Recommendations of the 1st International Consultation on Erectile Dysfunction. Anderson KE, Becher E, Hendry B, et al. Erectile dysfunction. Plymouth, UK: Health Publication Ltd, 2000: 709-26
2. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999 Jan; 161 (1): 5-11
3. Ralph D, McNicholas T, Erectile Dysfunction Alliance. UK management guidelines for erectile dysfunction. BMJ 2000 Aug 19; 321: 499-503
4. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995 Nov; 22 (4): 699-709
5. Nehra A, Pryor J, Althof SE, et al. Second international conference on management of erectile dysfunction: new perspectives on treatment. Int J Impot Res 2002; 14 Suppl. 1: S1-5
6. Vitezic D, Pelcic JM. Erectile dysfunction: oral pharmacotherapy options. Int J Clin Pharmacol Ther 2002 Sep; 40 (9): 393-403
7. Lue TF. Drug therapy: erectile dysfunction. N Engl J Med 2000 Jun 15; 342 (24): 1802-13
8. Nehra A, Barrett DM, Moreland RB. Pharmacotherapeutic advances in the treatment of erectile dysfunction. Mayo Clin Proc 1999 Jul; 74: 709-21
9. Rotella DP. Phosphodiesterase type 5 inhibitors: discovery and therapeutic utility. Drugs Future 2001; 26 (2): 153-62
10. Melman A, Christ GJ. The hemodynamics of erection and the pharmacotherapies of erectile dysfunction. Heart Disease 2002; 4 (4): 252-64
11. Giuliano F. Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J Suppls 2002; 4 Suppl. H: H7-H12
12. Andersson KE, Hedlund P. New directions for erectile dysfunction therapies. Int J Impot Res 2002; 14 Suppl. 1: S82-92
13. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001 Oct; 13 (5): 282-90
14. Saenz de Tejada I, Angulo Frutos J, Gaudo M, et al. Comparative selectivity profiles of tadalafil, sildenafil, and vardenafil using an in vitro phosphodiesterase activity assay [abstract no. P-081]. 5th Congress of the European Society for Sexual and Impotence Research; 2002 Dec 1-4; Hamburg
15. Gbekor E, Bethell S, Fawcett L, et al. Phosphodiesterase 5 inhibitor profiles against all human phosphodiesterase families: implications for use as pharmacological tools [abstract no. 967]. J Urol 2002 May; 167 (4 Suppl.): 246
16. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998 Jun; 159: 2164-71
17. Kim NN, Huang Y-H, Goldstein I, et al. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 2001 Sep 28; 69 (19): 2249-56
18. Bischoff E, Niewoehner U, Haning H, et al. The oral efficacy of vardenafil hydrochloride for inducing penile erection in a conscious rabbit model. J Urol 2001 Apr; 165 (4): 1316-8
19. Bischoff E, Schneider K. A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. Int J Impot Res 2001 Aug; 13 (4): 230-5
20. Bischoff E, Mondritzki T, Niewoehner U, et al. Vardenafil improved erections in rabbits longer than expected from plasma half-life [abstract]. 5th Congress of the European Society for Sexual and Impotence Research; 2002 Dec 1-4; Hamburg
21. Choi S, O'Connell L, Min K, et al. Efficacy of vardenafil and sildenafil in facilitating penile erection in an animal model. J Androl 2002; 23 (3): 332-7
22. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001 Feb; 19 (1): 32-9
23. Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001 Aug; 40 (2): 181-90
24. Padma-Nathan H, Kaufman J, Taylor T. Earliest time of onset of erections with vardenafil determined in an at-home setting [abstract no. 41]. Satellite Symposium at the 98th Annual Meeting of the American Urological Association; 2003 Apr 25; Chicago (IL)
25. Mazzu AL, Nicholls AJ, Zinny M. Vardenafil, a new selective PDE-5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged male subjects [abstract no. 19]. Int J Imp Res 2001; 13 Suppl. 5: S64
26. Young JM. Vardenafil. Expert Opin Investig Drugs 2002 Oct; 11 (10): 1487-96
27. European Agency for Evaluation of Medicinal Products. Vardenafil: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 Mar 20]
28. Bayer Pharmaceuticals Corporation/GlaxoSmithKline. Levitra® (vardenafil HCl) tablets: prescribing information [online]. Available from URL: http://www.levitra.com [Accessed 2003 Aug 22]
29. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002 Dec 4; 40 (11): 2006-12
30. Thadani U, Chrysant S, Mazzu A, et al. The effect of vardenafil, a selective PDE5 inhibitor, on ischemic threshold, exercise tolerance, and circulatory responses during treadmill exercise in men with stable angina pectoris [abstract no. 1026-104]. J Am Coll Cardiol 2003 Mar 19; 41 (6 Suppl. A): 336
31. Rohde G, Jordan PJ. Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy [abstract no. 90]. Pharmacotherapy 2002 Mar; 22 (3): 418
32. Hellstrom WJG, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23 (6): 763-71
33. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003 Mar; 26 (3): 777-83
34. Kloner RA, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction; an analysis of five placebo-controlled clinical trials [abstract no. 304]. Pharmacotherapy 2002 Oct; 22 (10): 1371
35. Bauer RJ, Rohde G, Taylor T, et al. A single oral dose of vardenafil had no acute effect on sperm motility in healthy males [abstract no. 2]. J Androl 2002; 23 Suppl. 1: 26
36. Klotz T, Bauer R-J, Rohde G, et al. Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor, for the treatment of erectile dysfunction [abstract no. 92]. Pharmacotherapy 2002; 22 (3): 418
37. Steidle CP, Feldman RA, Lettieri J, et al. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data of efficacy and safety in elderly patients with erectile dysfunction [abstract no. P289]. J Am Geriatr Soc 2001 Apr; 49 (4): S103
38. Rohde G, Wensing G, Sachse R. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, are not affected by the antacid, Maalox 70™ [abstract no. 2]. Pharmacotherapy 2001 Oct; 21 (10): 1254
39. Rohde G, Wensing G, Unger S, et al. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, is minimally affected by coadministration with cimetidine or ranitidine [abstract no. 3]. Pharmacotherapy 2001 Oct; 21 (10): 1254
40. Rohde G, Bauer R-J, Unger S, et al. Vardenafil, a new selective PDE5 inhibitor, produces no interaction with digoxin [abstract no. 4]. Pharmacotherapy 2001 Oct; 21 (10): 1254
41. Bauer RJ, Rohde G, Wensing G. The interaction of alcohol with vardenafil, a potent and highly selective phosphodiesterase type 5 inhibitor [abstract no. 91]. Pharmacotherapy 2002 Mar; 22 (3): 418
42. Rajagopalan P, Mazzu A, Xia C, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003 Mar; 43 (3): 260-7
43. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001 Aug; 13 (4): 192-9
44. Saenz de Tejada I, Glina S, Becher E, et al. Vardenafil exhibits long-term efficacy and safety for up to 52 weeks [abstract no. P-090]. 5th Congress of the European Society for Sexual and Impotence Research; 2002 Dec 1-4; Hamburg
45. Porst H, Giuliano F, Liyanage N. 6 month study shows sustained efficacy of vardenafil in treating ED [abstract no, PS-4]. 5th Congress of the European Society for Sexual and Impotence Research; 2002 Dec 1-4; Hamburg
46. Sotomavor M, Rubio E, Tapia R, et al. Vardenafil improved erectile function in Mexico: a 3-month, open-label study [abstract no. CP5.08]. Int J Impot Res 2002 Sep; 14 Suppl. 3: S88
47. Hatzichristou D, Montorsi F, Porst H, et al. A flexible dose regimen of vardenafil for erectile dysfunction: a placebo-controlled trial [abstract no. 014]. Eur Urol Suppl 2003; 2 (1): 176
48. Carson C, Hatzichristou D, Carrier S, et al. Vardenafil exhibits efficacy in men with erectile dysfunction unresponsive to prior sildenafil therapy: results of a phase III clinical trial - Patient Response with VardENafil in sildenafil nonresponders (PROVEN) [abstract no. 31]. Int J Impot Res 2003; 15 Suppl. 5: S175
49. Brock G, Taylor T, Seger M. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy [abstract no. 598]. Eur Urol Suppl 2002; 1 (1): 152 and poster from the XVIIth Congress of the European Association of Urology; 2002 Feb 23-26; Birmingham
50. Brock G, Taylor T, Seger M. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy [abstract no. 598]. Eur Urol Suppl 2002; 1 (1): 152 and poster from the XVIIth Congress of the European Association of Urology; 2002 Feb 23-26; Birmingham
51. Vezina JG, Nehra A, Brock G, et al. Vardenafil improved patient satisfaction with erection hardness, orgasmic function, and sexual experience in men with erectile dysfunction following nerve-sparing radical prostatectomy [abstract no. 949]. J Urol 2003 Apr; 169 (4 Suppl.): 245
52. Donatucci C, Pommerville P, Niederberger C, et al. Vardenafil improved patient satisfaction with erection hardness, orgasmic function, and sexual experience in men with erectile dysfunction [abstract no. 950]. J Urol 2003 Apr; 169 (4 Suppl.): 246
53. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (ILEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 Jun; 49 (6): 822-30
54. Fugl-Meyer AR, Lodnert G, Bränholm I-B, et al. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997 Sep; 9 (3): 141-8
55. Padma-Nathan H, Eardley I, Collins O, et al. Vardenafil restores normal functioning to men with erectile dysfunction [abstract no. 710]. J Urol 2002 Apr; 167 (4 Suppl.): 177
56. Donatucci C, Eardley I, McVary KT, et al. Vardenafil improves erectile function regardless of etiology or baseline severity in men with erectile dysfunction [abstract no. 715]. J Urol 2002 Apr; 167 (4 Suppl.): 178
57. Donatucci C, Karlin G, Goldfischer E, et al. Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction [abstract no. P293]. J Amer Ger Soc 2002; 50 Suppl. 4: S107
58. Goldfischer E, Eardley I, Segerson T. Vardenafil improves erectile function in men with significant comorbidities associated with erectile dysfunction [abstract no. 714]. J Urol 2002 Apr; 167 (4 Suppl.): 178
59. Hatzichristou DG, Pescatori ES. Current treatments and emerging therapeutic approaches in male erectile dysfunction. BJU Int 2001; 88 (Suppl. 3): 11-7
60. Porst H, Padma-Nathan H, Thibonnier M, et al. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy [abstract no. 599]. Eur Urol Suppl 2002 Jan; 1 (1): 152
61. Valiquette L, Hellstrom W, Gittelman M, et al. Vardenafil provides reliable efficacy over time in men with erectile dysfunction [abstract no. CP5.07]. Int J Impot Res 2002 Sep; 14 Suppl. 3: S88
62. Young JM, Goldstein I, Taylor T. Long-term efficacy and safety of vardenafil in diabetic men with erectile dysfunction [abstract no. 1033]. Diabetologia 2002 Aug; 45 Suppl. 2: 334-5
63. Young J, Goldstein I, Fishcer J, et al. Vardenafil (Levitra®) improved satisfaction with erectile hardness, orgasmic function, and sexual experience in men with diabetes with erectile dysfunction [abstract no. 68-OR]. Diabetes 2003 Jun; 52 Suppl. 1: A16
64. Stief C, Porst H, Saenz de Tejada I, et al. Sustained efficacy and tolerability of vardenafil over two years in men with erectile dysfunction [abstract no. 100]. Prog Urol 2003; 13 Suppl. 2: 31
65. Montorsi F, Hellstrom WJG, Valiquette L, et al. Reliable efficacy over time of vardenafil, a potent, highly selective PDE-5 inhibitor in men with erectile dysfinction: a retrospective analysis of two pivotal phase III studies [abstract no. 98]. Prog Urol 2003; 13 Suppl. 2: 31
66. Goldstein I Young JM, Fishcer JS, et al. Vardenafil (Levitra®) improved patient satisfaction with erectile hardness, orgasmic function, and sexual experience in men with erectile dysfunction and diabetes irrespective of level of glycemic control [abstract no, 917]. Diabetologia 2003; 46 Suppl. 2: A317
67. Hellstrom WJG, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003 Apr; 61 Suppl. 4A: 8-14
68. Porst H, Young JM, Schmidt AC, et al. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003 Sep; 62 (3): 519-23; discussion 523-4
69. Dey J, Shepherd MD. Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. Mayo Clin Proc 2002; 77 (3): 276-82
70. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994 Jan; 151 (1): 54-61
71. Wespes E, Amar E, Hatzichristou D, et al. Guidelines on erectile dysfunction. Eur Urol 2002 Jan; 41 (1): 1-5
72. Canadian Urological Association Guidelines Committee. Erectile dysfunction practice guidelines. Can J Urol 2002 Aug; 9 (4): 1583-7
73. Costabile RA. Alprostadil for the treatment of erectile dysfunction. Expert Opin Invest Drugs 1999 Jun; 8 (6): 877-84
74. Lyseng-Williamson KA, Wagstaff AJ. Management of erectile dysfunction: defining the role of sildenafil. Dis Manage Health Outcomes 2002; 10 (7): 431-52
75. Fulgham PF, Cochran JS, Denman JL, et al. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998 Dec; 160: 2041-6
76. Altwein JE, Keuler FU. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int 2001; 67: 257-63
77. European Agency for Evaluation of Medicinal Products. Apomorphine: summary of product characteristics [online]. Available from URL: http://emea.eu.int [Accessed 2003 Mar 24]
78. Borer J, Armstrong P. Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee: May 29th and 30th, 2003. Circulation 2003 Jun 17; 107 (23): e9052
79. Pfizer Inc., Viagra® (sildenafil citrate) prescribing information [online]. Available from URL: http://www/viagra.com/professional/pi/ proPackInsert.asp [Accessed 2003 Mar 24]
80. Jackson G, Betteridge J, Dean J, et al. A systematic approach to erectile dysfunction in the cardiovascular patient: a consensus statement - update 2002. Int J Clin Pract 2002; 56 (9): 663-71
81. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999; 99: 168-77
82. European Agency for Evaluation of Medicinal Products. Tadalafil: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 Mar 24]
83. Langtry HD, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999 Jun; 57: 967-89
84. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 Suppl. 1: S57-64
85. Porst H, Rosen RC, Padma-Nathan H, et al. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose [abstract no. 709]. J Urol 2002 Apr; 167 Suppl.: 177